Podofilox
Antivirals
Sold as Condylox
- Drug class
- Antivirals
- Availability
- Prescription only
- Routes
- Topical
- Markets covered
- 1
- Products on record
- 1
- FDA reports (12 mo)
- 1
Overview
Podofilox is an active pharmaceutical ingredient in the Antivirals group (D06BB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 1 | January 29, 2024 |
USUnited States· FDA
1 product
Uses
INDICATIONS AND USAGE
5% is indicated for the topical treatment of anogenital warts (external genital warts and perianal warts). This product is not indicated in the treatment of mucous membrane warts (see PRECAUTIONS ). Diagnosis Although anogenital warts have a characteristic appearance, histopathologic confirmation should be obtained if there is any doubt of the diagnosis.
Differentiating warts from squamous cell carcinoma and "Bowenoid papulosis" is of particular concern. 5%.
How to take
Sources & citations
- [1]FDA DailyMed · 032e4bcb-b1ed-40… · revised January 29, 2024 [PDF]
- [2]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.